|
|
|
|
Low-dose oral steroid use at the onset of interferon B-1b (IFNB-1b) therapy in relapsing-remitting multiple sclerosis (RR-MS) patients reduces flulike symptoms. To determine the mechanism by which steroid treatment minimizes these side effects, we analyzed the percentage of interleukin-6 (IL-6)-, interferon-Y(IFN-Y)-, tumor recrosis factor x(TNF-x)-, and IL-10-producing cells before and after 3 months of IFNB-1b therapy onset. Our results support a relationship between IL-6 induction and fever. Such side effects can be ameliorated by steroids. |
|